MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock […]
Other News
Lantheus Receives U.S. FDA Approval of New Manufacturing Facility
On-site plant will produce DEFINITY® (Perflutren Lipid Microsphere), the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms NORTH BILLERICA, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial […]
Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device
HOUSTON–(BUSINESS WIRE)–Saranas, a company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications, announced today that the U.S. Department of Commerce’s United States Patent and Trademark Office (USPTO) has issued them Patent No. 11,224,414. Titled “Access Closure with Bleed Monitoring,” this key patent allows for embedding […]
Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy Devices
Mechanical and aspiration devices to treat peripheral vascular disease, deep vein thrombosis and pulmonary embolism ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today it has partnered with Innova […]
Eko Welcomes Eric Davidson as President
Former Johnson & Johnson, Auris Health, and Intuitive Surgical Exec to Lead Eko’s Commercial Expansion OAKLAND, Calif., Feb. 23, 2022 /PRNewswire/ — Eko, a digital health company advancing heart and lung disease detection, today announced the appointment of Eric Davidson as President and Chief Operating Officer. Davidson joins Eko from Johnson & Johnson, where he […]
Medtronic reports third quarter fiscal 2022 financial results
Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN, Feb. 22, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2022, which ended January 28, 2022. Key Highlights Revenue of $7.8 billion was flat year-over-year […]
MicroVention Announces First U.S. Patient Treated with FRED™ X™ Flow Diverter Featuring X Technology
ALISO VIEJO, Calif., Feb. 22, 2022 /PRNewswire/ — MicroVention, Inc., a subsidiary of Terumo and a global neurovascular company, announced the first U.S. clinical case of its next generation Flow Diverter, the FRED X device, at Thomas Jefferson University Hospital located in Philadelphia. MicroVention received FDA PMA approval for the FRED X device in September […]
TLV recommends AliveCor’s smartphone-based ECG as a more cost-effective option for the detection of atrial fibrillation compared to Holter ECG
Sweden’s Dental and Pharmaceutical Benefits Agency, TLV evaluated the combination of the KardiaMobile® and KardiaPro personal electrocardiogram (ECG) and software compared to the current standard of care, Holter ECG The health economic assessment found a higher degree of atrial fibrillation (AF) detection and resource-saving with KardiaMobile compared to Holter ECG 24 hours1 KardiaMobile […]
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
– Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 12% Sequentially to $12.2 Million in the Fourth Quarter 2021 and Over 200% for the Full Year 2021 – – Prescriptions Grew 9% […]
Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has received comments from the Australian Human Research Ethics Committee (the “HREC”) regarding the Company’s Phase 1 clinical study of R-107, and […]



